SCHEMBL3489826

SCHEMBL3489826

Cn1ccnc1-c1cccc(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NMT1 P30419 1/20 0.47
ALDH1A1 P00352 5/20 0.44
MAPT P10636 4/20 0.44
MAPK1 P28482 2/20 0.44
RAB9A P51151 2/20 0.44
RECQL P46063 1/20 0.44
MC4R P32245 2/20 0.43
HSD17B10 Q99714 3/20 0.42
APOBEC3G Q9HC16 2/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.42
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
RIPK2 O43353 1/20 0.42
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TGFBR1 P36897 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14412223 0.87 NMT1 (0.52) NMT1RAB9AHSD17B10KDM4ENPC1
SCHEMBL12759448 0.84 TGFBR1 (0.48) NMT1ALDH1A1MAPTRAB9ARIPK2
SCHEMBL17264894 0.82 NMT1 (0.52) NMT1RAB9AHSD17B10KDM4ENPC1
SCHEMBL31319322 0.80 MC4R (0.41) NMT1ALDH1A1MAPTRAB9ARECQL
SCHEMBL12277262 0.80 MC4R (0.44) ALDH1A1MAPTMAPK1RAB9AMC4R
SCHEMBL29711750 0.79 HSD17B2 (0.48) NMT1RIPK2NTRK1
SCHEMBL28469346 0.79 NMT1 (0.44) NMT1RAB9AHSD17B10KDM4ENPC1
SCHEMBL3488664 0.79 IDO1 (0.49) NMT1ALDH1A1MAPTRAB9AAPOBEC3G
SCHEMBL12320076 0.79 KDR (0.47) NMT1ALDH1A1HSD17B10KDM4ERIPK2
SCHEMBL3970148 0.79 MAP4K4 (0.46) NMT1ALDH1A1MAPTRAB9ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105229009-B 2-phenylimidazo [1,2-A ] pyrimidines as imaging agents 豪夫迈·罗氏有限公司 2017-09-29 CN claimed
CN-105229009-A 2-phenylimidazo [1,2-A ] pyrimidines as imaging agents HOFFMANN LA ROCHE 2016-01-06 CN claimed
US-12120945-B2 Display and lighting devices comprising phosphorescent excimers with preferred molecular orientation as monochromatic emitters ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2024-10-15 US disclosed
US-20240239825-A1 1,8-SUBSTITUTED CARBAZOLE-BASED PLATINUM COMPLEXES WITH HIGH RADIATION RATE AND APPLICATION THEREOF ZHEJIANG HUAXIAN PHOTOELECTRICITY TECHNOLOGY CO., LTD (CN) 2024-07-18 US disclosed
US-20240239825-A1 1,8-SUBSTITUTED CARBAZOLE-BASED PLATINUM COMPLEXES WITH HIGH RADIATION RATE AND APPLICATION THEREOF ZHEJIANG HUAXIAN PHOTOELECTRICITY TECHNOLOGY CO., LTD (CN) 2024-07-18 US disclosed
CN-118201921-A Lactams as CBL-B inhibitors selective for C-CBL 基因泰克公司 2024-06-14 CN disclosed
US-11925104-B2 Organometallic compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2024-03-05 US disclosed
CN-117279468-A Phosphorescent excimer with preferred molecular orientation as monochromatic emitter for display and illumination applications 李健 2023-12-22 CN disclosed
CN-109280063-B Organometallic compound and organic light emitting device including the same 三星显示有限公司 2023-12-12 CN disclosed
CN-111527615-B Phosphorescent excimer with preferred molecular orientation as monochromatic emitter for display and illumination applications 李健 2023-10-17 CN disclosed
US-20230247897-A1 Phosphorescent Excimers with Preferred Molecular Orientation as Monochromatic Emitters for Display And Lighting Applications UNITED STATES DEPARTMENT OF ENERGY 2023-08-03 US disclosed
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators SGX PHARMACEUTICALS, INC. 2010-02-11 US disclosed
EP-2134179-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
WO-2008124850-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, TTK, MAP3K19 NMT1 2599/4885ALDH1A1 4383/4885MAPT 3150/4885
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators MAP3K20, TTK, MAP3K19 NMT1 2599/4885ALDH1A1 4383/4885MAPT 3150/4885
US-20240239825-A1 1,8-SUBSTITUTED CARBAZOLE-BASED PLATINUM COMPLEXES WITH HIGH RADIATION RATE AND APPLICATION THEREOF LIG3, VIM, TRIM33 NMT1 492/4885ALDH1A1 3843/4885MAPT 786/4885
US-11925104-B2 Organometallic compound and organic light-emitting device including the same LEF1, GPX1, ODC1 NMT1 1196/4885ALDH1A1 6/4885MAPT 1570/4885
US-12120945-B2 Display and lighting devices comprising phosphorescent excimers with preferred molecular orientation as monochromatic emitters PDCD1LG2, EML4, EMC3 NMT1 1193/4885ALDH1A1 2482/4885MAPT 489/4885
US-20230247897-A1 Phosphorescent Excimers with Preferred Molecular Orientation as Monochromatic Emitters for Display And Lighting Applications PDCD1LG2, DCX, EMC2 NMT1 1048/4885ALDH1A1 2808/4885MAPT 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.